Prediction: Procter & Gamble Will Trade At This Price in 2027

Photo of Vandita Jadeja
By Vandita Jadeja Published

Quick Read

  • Procter & Gamble (PG) reported Q3 FY2026 Core EPS of $1.59, beating the $1.55 consensus, with revenue of $21.23B up 7.4% YoY and five consecutive earnings beats, while the stock trades 14% below its 52-week high despite delivering broad-based growth across all segments and regions.

  • PG trades at a discount despite fundamental strength due to tariff headwinds ($400M after-tax) and margin compression, but the company’s Portfolio/Supply Chain Productivity Plan targets $1.5B in cost-of-goods-sold savings and 7,000 role reductions by end of FY2027, positioning it as a defensive cash machine with a 70-year dividend streak yielding 3%.

  • The analyst who called NVIDIA in 2010 just named his top 10 stocks and P&G wasn't one of them. Get them here FREE.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Prediction: Procter & Gamble Will Trade At This Price in 2027

© Public Domaine / Wikimedia Commons

Our 24/7 Wall St. price target for Procter & Gamble (NYSE:PG | PG Price Prediction) is $163.50, implying a 14.95% upside from today’s price. Procter & Gamble trades at $142.24 as of May 13, 2026, with a $330.7 billion market cap and a beta of 0.4.

Our recommendation is buy, with 90% confidence. PG is a defensive cash machine trading well below recent highs, supported by analyst consensus and stable earnings power.

An infographic titled 'Procter & Gamble 12-Month Price Prediction' by 24/7 Wall St. The call is 'BUY' at $163.50, representing a +14.95% increase from $142.24, with 90% confidence. A 'How We Got There' section displays horizontal bars for Trailing P/E ($142.24), Forward P/E ($149.60), and Analyst Consensus ($163.77, with 30% weight), leading to a Weighted Base of $152.38. The 'Our Adjustments' section features a waterfall chart beginning with a Base of $152.38, followed by positive adjustments labelled Sector Momentum (+0.035), Analyst Consensus (58% Bullish, +0.006), Earnings Growth (5.8% YoY, +0.012), Volatility Adjustment (Beta 0.4, +0.015), Price Position (Near 52W High, +0.009), Social Sentiment (Score 62), and a large red negative adjustment for Market Cap Dampening (-50%), culminating in a Final Target of $163.50 (1.073 247Factor). The 'Bull Case' section, shown in green, outlines 'What Could Go Right' with icons for 'Portfolio & Productivity Plan (7k role reductions)', 'Supply Chain 3.0 Savings ($1.5B target)', and 'Innovation & Emerging Markets (Synthetic Bio, India/China)', yielding a target of $174.78 (Total Return +22.87%). The 'Bear Case' section, in red, details 'What Could Go Wrong' with icons for 'Tariff Exposure ($400M after-tax headwind)', 'Core Gross Margin Pressure (-100 bps Q3)', and 'Insider Selling ($39.7M over 90 days)', resulting in a target of $151.07 (Total Return +6.21%). The 'The Bottom Line' section reiterates 'BUY $163.50 (+14.95%)' with a description: 'Defensive cash machine trading below highs, supported by earnings power and analyst consensus, despite tariff risks.'
24/7 Wall St.
Metric Value
Current Price $142.24
24/7 Wall St. Price Target $163.50
Upside 14.95%
Recommendation BUY
Confidence Level 90%

A Defensive Name That Sold Off Into Earnings Strength

PG is down 7.84% over 12 months, off 3.83% in the past week, and barely positive year to date at +0.69%. Shares sit roughly 14% below the 52-week high of $166.21 and well above the 52-week low of $135.63.

Fundamentals don’t justify the weakness. Q3 FY2026, filed April 24, 2026, delivered Core EPS of $1.59 against a $1.55 consensus, with revenue of $21.23 billion, up 7.4% YoY. Beauty grew 7% organic, and every segment posted growth. CEO Shailesh Jejurikar said the quarter showed “a solid acceleration in top-line results… broad-based growth across product categories and regions.” That marks five consecutive earnings beats.

The Case for $175+

The bull case is credible. Our model’s bull scenario points to $174.78 by May 2027, a 22.87% total return. Drivers include the Portfolio, Supply Chain and Productivity Plan targeting up to 7,000 non-manufacturing role reductions by end of FY2027, plus a Supply Chain 3.0 program aimed at $1.5 billion in cost-of-goods-sold savings. Innovation in synthetic biology, premium Skin Care mix, and emerging-market penetration in India, MEA, and Greater China underpin the multi-year story.

External analysts agree. Simply Wall St’s DCF model pegs PG as 21.3% undervalued, citing a P/E of 21x versus a fair ratio of 24x. Jim Cramer recently flagged the stock as a hedge against economic slowdown given its valuation. The dividend, now at $1.0885 quarterly with a 3% yield, marks PG’s 70th consecutive annual increase.

The Risks Worth Watching

The bear case is real. Tariffs represent a $400 million after-tax headwind, and management flagged FY2026 results toward the low end of guidance. Q3 core gross margin compressed 100 basis points. Zacks issued a Sell rating, citing moderating sales growth and premium valuation. Insiders have sold roughly $39.7 million in shares over the past 90 days.

Bulls argue margin pressure reflects deliberate reinvestment in innovation and demand creation, and that gross productivity savings of 210 basis points partially offset tariff and mix headwinds. Our bear case scenario lands at $151.07, still a 6.21% positive return.

Procter & Gamble Price Prediction 2026-2030

The 24/7 Wall St. price target is $163.50, a buy with 90% confidence. The combination of a defensive sector profile, a beta near 0.4, and analyst consensus of $163.77 on a stock that has absorbed tariff fears tips the scale. The setup favors investors seeking compounding dividends and downside protection, while FY2027 oil-driven cost shocks beyond what management has telegraphed remain the key risk to monitor.

Here is where our model projects PG could trade, assuming current growth trajectories hold.

Year 24/7 Wall St. Price Target
2026 $163.50
2027 $176.00
2028 $190.00
2029 $206.00
2030 $224.36

These projections assume PG continues executing its integrated growth strategy and productivity plan. Significant upside or downside could result from tariff escalation, raw-material shocks, or accelerated emerging-market expansion.

Photo of Vandita Jadeja
About the Author Vandita Jadeja →

Vandita Jadeja is a financial copywriter who loves to read and write about stocks. She believes in buying and holding for long term gains. Her knowledge of words and numbers helps her write clear stock analysis. She has contributed to several publications, including the Joy Wallet, Benzinga, The Motley Fool and InvestorPlace.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

ENPH Vol: 20,331,230
DXCM Vol: 11,133,392
FDS Vol: 1,192,775
WDAY Vol: 5,160,389
NOW Vol: 34,569,747

Top Losing Stocks

CTRA Vol: 73,319,495
GLW Vol: 17,221,470
COIN Vol: 14,429,129
F Vol: 108,272,348
MU Vol: 48,532,352